Informing Treatment Decisions in Psoriatic Arthritis: The Value of Network Meta-Analyses

Network meta-analysis is a technique used for comparing several interventions simultaneously. NMAs are often used by regulators, health technology assessment agencies, and medical guideline committees. However, there is also a very important place for them in treatment decisions.    

Decision time
• Source: Shutterstock

Active psoriatic arthritis (PsA), a chronic, progressive, immune-mediated disease, is also a heterogeneous disease with symptoms that may include joint inflammation, scaly patches on the skin, nail disease, enthesitis, dactylitis, and/or axial disease. In addition to symptoms of pain, stiffness and swelling in and around the joints, people with PsA can suffer from numerous comorbidities including obesity, cardiovascular diseases, anxiety, and depression. If not treated early, the disease may cause permanent joint and spine damage, and loss of functionality.

Though there are many therapies available for active PsA, patients sometimes respond differently to the varying treatments, adding to the...

More from Innovation

More from In Vivo

EU Medtech Outlook: The View From MedTech Europe Experts

 
• By 

MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.

‘Confident In Lorundrostat’s Promise’: Mineralys CEO Talks Trials And Next Steps

 

In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.

BioBytes: Qubit Pharmaceuticals Unveils Quantum AI Model For Drug Discovery

 
• By 

Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.